StoneX Group
PMCB icon

StoneX Group’s PharmaCyte Biotech PMCB Stock Holding History

StoneX Group’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.3K Buy
+30,006
New +$16.5K ﹤0.01% 1827

Other funds holding PMCB

Equitec Proprietary Markets
Equitec Proprietary Markets Chicago, Illinois $400M AUM 66.98% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
BFSG LLC
BFSG LLC Irvine, California $1.14B AUM 21.04% 1-Year Est. Return
Financial Consulate
Financial Consulate Hunt Valley, Maryland $899M AUM 14.82% 1-Year Est. Return

StoneX Group's PMCB Position: Q3 2026 in Review

StoneX Group opened a new position in PharmaCyte Biotech (PMCB) in Q3 2026: 30,006 shares worth $12.3K. The stake represents ﹤0.01% of the portfolio and ranks #1827 among its holdings.

6 funds tracked by Wall St. Rank hold PMCB as of Q3 2026.

  • StoneX Group held 30,006 shares of PharmaCyte Biotech worth $12.3K as of Q3 2026.
  • PharmaCyte Biotech was a new StoneX Group position in Q3 2026.
  • PharmaCyte Biotech made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1827 holding.
  • 6 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.